Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Endocrinology

Metabolic Complications: How AKT2 Affects Your Health

At a Glance

AKT2-related familial partial lipodystrophy disrupts fat storage and insulin signaling, raising the risk of early diabetes, very high triglycerides, fatty liver, pancreatitis, and reproductive or pregnancy complications. Testing may detect problems before symptoms appear.

To understand why AKT2-related disease causes so many different health issues, it helps to think of the AKT2 protein as a master traffic controller for energy [1]. When you eat, your body releases insulin to tell your cells to either burn sugar for fuel or store it as fat for later. In your case, the “bridge” that carries this signal—the AKT2 pathway—is not working correctly [2][3].

Because the message to “store fat here” never reaches the fat cells in your arms and legs, the energy (in the form of fats called lipids) has nowhere to go. It begins to “spill over” into places it doesn’t belong, like your blood, your liver, and your muscles [4][5]. This spillover causes the metabolic complications associated with your diagnosis.

(Note: Because AKT2 variants are so rare, much of what we know about these complications comes from studying broader cohorts of people with other forms of FPLD. Your specific risks may vary depending on your variant.)

Severe Insulin Resistance and Diabetes

The most immediate consequence of a broken AKT2 signal is severe insulin resistance [3]. Your body may produce massive amounts of insulin, but your cells simply cannot hear the command to take up sugar from the blood.

  • Early-Onset Diabetes: Many people with FPLD develop diabetes at a young age, often starting around puberty [5][6].
  • The Hidden Risk: Standard blood tests can be misleading. Research on broader FPLD cohorts shows that up to 86% of people who have “normal” fasting blood sugar levels actually have impaired glucose tolerance when given a “challenge” [7]. For this reason, experts recommend an Oral Glucose Tolerance Test (OGTT)—where you drink a sugary liquid and have your blood drawn over several hours—to get a true picture of how your body handles sugar [7][8].

Blood Fats and the Risk of Pancreatitis

When fat cannot be stored under the skin, it circulates in the blood as triglycerides [5]. In FPLD, these levels can become “severely elevated,” meaning they are many times higher than what is considered healthy [9][10].

The greatest danger of extremely high triglycerides is acute pancreatitis, a painful and serious inflammation of the pancreas [11][5]. This risk is significantly higher if you also have uncontrolled diabetes [11][12]. Warning signs that require immediate medical attention include severe abdominal pain that feels like it is “boring” through to your back, often accompanied by nausea and vomiting [13].

Fatty Liver Disease (Hepatic Steatosis)

The liver is often the first place “homeless” fat goes to hide. This is called hepatic steatosis, or fatty liver [4].

  • Progression: Over time, the fat in the liver can cause inflammation (steatohepatitis), which may lead to permanent scarring (fibrosis) or even cirrhosis [14][15].
  • Monitoring: Because you cannot “feel” your liver getting fatty, doctors use ultrasound, MRI, or transient elastography (often called a FibroScan) to monitor the health of your liver tissue [14][16].

Reproductive and Hormonal Challenges

For women, the high levels of insulin caused by AKT2 variants can interfere with the ovaries. This often leads to a condition that looks exactly like Polycystic Ovary Syndrome (PCOS) [17][2].

  • Symptoms: This may include irregular periods, difficulty conceiving, and hyperandrogenism (signs of high male hormones like excess facial hair or acne) [18][17].
  • Pregnancy Risks: While many women with FPLD have healthy pregnancies, there is a higher risk of gestational diabetes and dangerous spikes in triglycerides during pregnancy [19][20]. If you are planning a family, it is vital to work with a high-risk obstetrician and an endocrinologist who understands lipodystrophy [16][20].

Summary of Common Metabolic Findings

Feature What it is Why it happens in AKT2-FPLD
Hypertriglyceridemia High blood fats Fat has no “room” in the limbs and stays in the blood [5].
Acanthosis Nigricans Dark, velvety skin patches A physical sign that your insulin levels are extremely high [21].
Low HDL Low “good” cholesterol Often part of the “metabolic package” seen in insulin resistance [9].
Hepatic Fibrosis Liver scarring The result of long-term fat storage and inflammation in the liver [14].

Common questions in this guide

Why can AKT2-related familial partial lipodystrophy cause severe insulin resistance?
AKT2 helps insulin signal cells to use or store energy. When this signal is disrupted, fat cannot be stored normally in the limbs, so excess fat can build up in the blood, liver, and muscles and make it harder for cells to respond to insulin. This can lead to diabetes, sometimes at a young age.
Can a normal fasting blood sugar miss diabetes risk in AKT2-FPLD?
A normal fasting blood sugar does not always show how the body handles sugar in familial partial lipodystrophy. An oral glucose tolerance test, which measures blood sugar after a measured sugary drink, may detect impaired glucose handling that a fasting test misses. Ask your endocrinologist whether this test is appropriate for you.
How do high triglycerides increase pancreatitis risk in FPLD?
Very high triglycerides can trigger acute pancreatitis, a serious inflammation of the pancreas, and the risk is higher when diabetes is not controlled. Severe abdominal pain that may spread to the back, especially with nausea or vomiting, requires immediate medical attention. Your clinician can explain your latest triglyceride result and whether you need urgent or preventive care.
How is fatty liver monitored in AKT2-related FPLD?
Fatty liver may cause no noticeable symptoms, so clinicians may use ultrasound, MRI, or transient elastography, also called a FibroScan, to assess liver fat and stiffness. These tests can help look for inflammation or scarring over time. Your care team can decide which test and follow-up schedule fit your situation.
Can AKT2-related FPLD affect periods, fertility, or pregnancy?
High insulin levels can cause irregular periods, difficulty conceiving, acne, or excess facial hair that resemble polycystic ovary syndrome. Pregnancy can increase the risk of gestational diabetes and dangerous triglyceride elevations. If you are planning pregnancy, coordinate care with an endocrinologist and a high-risk obstetrician.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Should I have an oral glucose tolerance test (OGTT) even if my fasting blood sugar is normal?
  2. 2.What was my last triglyceride level, and am I at high risk for pancreatitis?
  3. 3.Can we check my liver for signs of fibrosis or scarring using transient elastography (FibroScan) or specialized imaging?
  4. 4.If I am planning a pregnancy, what specialized monitoring do I need to manage my blood sugar and triglyceride levels?
  5. 5.Does my AKT2 variant make me more likely to have PCOS-like symptoms, and how should we manage them?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    AKT/PKB Signaling: Navigating the Network.

    Manning BD, Toker A

    Cell 2017; (169(3)):381-405 doi:10.1016/j.cell.2017.04.001.

    PMID: 28431241
  2. 2

    Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.

    Gambineri A, Zanotti L

    Nucleus (Austin, Tex.) 2018; (9(1)):392-397 doi:10.1080/19491034.2018.1509659.

    PMID: 30131000
  3. 3

    A family with severe insulin resistance and diabetes due to a mutation in AKT2.

    George S, Rochford JJ, Wolfrum C, et al.

    Science (New York, N.Y.) 2004; (304(5675)):1325-8 doi:10.1126/science.1096706.

    PMID: 15166380
  4. 4

    Familial Partial Lipodystrophy (FPLD): Recent Insights.

    Bagias C, Xiarchou A, Bargiota A, Tigas S

    Diabetes, metabolic syndrome and obesity : targets and therapy 2020; (13()):1531-1544 doi:10.2147/DMSO.S206053.

    PMID: 32440182
  5. 5

    Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

    Mosbah H, Donadille B, Vatier C, et al.

    Orphanet journal of rare diseases 2022; (17(Suppl 1)):170 doi:10.1186/s13023-022-02308-7.

    PMID: 35440056
  6. 6

    Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.

    Zhong ZX, Harris J, Wilber E, et al.

    Clinical endocrinology 2022; (97(6)):755-762 doi:10.1111/cen.14806.

    PMID: 35920656
  7. 7

    Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes.

    Treiber G, Guilleux A, Huynh K, et al.

    Diabetes & metabolism 2023; (49(2)):101409 doi:10.1016/j.diabet.2022.101409.

    PMID: 36400409
  8. 8

    Endoplasmic reticulum stress activation in adipose tissue induces metabolic syndrome in individuals with familial partial lipodystrophy of the Dunnigan type.

    Foss-Freitas MC, Ferraz RC, Monteiro LZ, et al.

    Diabetology & metabolic syndrome 2018; (10()):6 doi:10.1186/s13098-017-0301-6.

    PMID: 29449893
  9. 9

    A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies.

    Treiber G, Flaus Furmaniuk A, Guilleux A, et al.

    European journal of endocrinology 2021; (185(4)):453-462.

    PMID: 34292171
  10. 10

    Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants.

    Vasandani C, Li X, Sekizkardes H, et al.

    Journal of the Endocrine Society 2022; (6(12)):bvac155 doi:10.1210/jendso/bvac155.

    PMID: 36397776
  11. 11

    Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2.

    Lazarte J, Wang J, McIntyre AD, Hegele RA

    Journal of clinical lipidology 2021; (15(5)):653-657 doi:10.1016/j.jacl.2021.07.004.

    PMID: 34340952
  12. 12

    A Comprehensive Update on the Chylomicronemia Syndrome.

    Goldberg RB, Chait A

    Frontiers in endocrinology 2020; (11()):593931 doi:10.3389/fendo.2020.593931.

    PMID: 33193106
  13. 13

    The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.

    Chait A, Eckel RH

    Annals of internal medicine 2019; (170(9)):626-634 doi:10.7326/M19-0203.

    PMID: 31035285
  14. 14

    Waist circumference is independently associated with liver steatosis and fibrosis in LMNA-related and unrelated Familial Partial Lipodystrophy women.

    Viola LF, Valerio CM, Araujo-Neto JM, et al.

    Diabetology & metabolic syndrome 2023; (15(1)):182 doi:10.1186/s13098-023-01156-0.

    PMID: 37679847
  15. 15

    Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl.

    Krawiec P, Mełges B, Pac-Kożuchowska E, et al.

    BMC pediatrics 2016; (16()):38 doi:10.1186/s12887-016-0581-2.

    PMID: 26976018
  16. 16

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244
  17. 17

    Familial partial lipodystrophy as differential diagnosis of polycystic ovary syndrome.

    Lewandowski KC, Lewiński A, Dąbrowska K, et al.

    Endokrynologia Polska 2015; (66(6)):550-4 doi:10.5603/EP.2015.0067.

    PMID: 26662654
  18. 18

    Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review.

    Fernandez-Pombo A, Diaz-Lopez EJ, Castro AI, et al.

    Cells 2023; (12(5)) doi:10.3390/cells12050725.

    PMID: 36899861
  19. 19

    Gestational and neonatal outcomes of women with partial Dunnigan lipodystrophy.

    Valerio CM, Muniz RBG, Viola LF, et al.

    Frontiers in endocrinology 2024; (15()):1359025 doi:10.3389/fendo.2024.1359025.

    PMID: 38633761
  20. 20

    First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report.

    Holstein A, Jabri I, Linck JA, et al.

    Frontiers in endocrinology 2026; (17()):1855679 doi:10.3389/fendo.2026.1855679.

    PMID: 42440509
  21. 21

    Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?

    Vatier C, Vigouroux C, Mosbah H

    Annales d'endocrinologie 2024; (85(3)):190-194 doi:10.1016/j.ando.2024.05.019.

    PMID: 38871502

This page is for informational purposes only and is not medical advice. Your endocrinologist and other clinicians can interpret your glucose, triglyceride, liver, and reproductive risks.

Get notified when new evidence is published on AKT2-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.